[
  {
    "ts": null,
    "headline": "Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
    "summary": "The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
    "url": "https://finnhub.io/api/news?id=9fc128ffa1bd92857548e11b9282c0e28873d4b5dcefbf9463a7e3226b50f9d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765324388,
      "headline": "Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
      "id": 137749929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
      "url": "https://finnhub.io/api/news?id=9fc128ffa1bd92857548e11b9282c0e28873d4b5dcefbf9463a7e3226b50f9d3"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "Medincell Publishes its Consolidated Half-Year Financial Results",
    "summary": "MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): \"We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin",
    "url": "https://finnhub.io/api/news?id=8392234a185d5b089d800b632672c36cbc2f0ace446c3453ff496cb01b50344b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299720,
      "headline": "Medincell Publishes its Consolidated Half-Year Financial Results",
      "id": 137742615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): \"We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin",
      "url": "https://finnhub.io/api/news?id=8392234a185d5b089d800b632672c36cbc2f0ace446c3453ff496cb01b50344b"
    }
  },
  {
    "ts": null,
    "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
    "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296917,
      "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
      "id": 137741749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Buy in December",
    "summary": "Great dividends are only part of the attraction with these stocks.",
    "url": "https://finnhub.io/api/news?id=3280355bbb549d40c5fad897dd7a0dc6ff1d4e45ba53dca390ebefa1a0698344",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765274640,
      "headline": "3 Top Dividend Stocks to Buy in December",
      "id": 137740127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Great dividends are only part of the attraction with these stocks.",
      "url": "https://finnhub.io/api/news?id=3280355bbb549d40c5fad897dd7a0dc6ff1d4e45ba53dca390ebefa1a0698344"
    }
  }
]